Skip to main content

Brege Laura

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Brege Laura as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

MIRM Mirum Pharmaceuticals, Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 12, 2025 (view filing)Sep 111 dayBrege LauraDirectorSSale−17.0K$74.40−$1.26M−52.0%15.7K after2 lots

ACAD Acadia Pharmaceuticals Inc

Director3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 5, 2025 (view filing)Jun 41 dayBrege LauraDirectorSSale−14.4K$21.78−$314.6K−48.9%15.1K after
Jun 14, 2023 (view filing)Jun 122 daysBrege LauraDirectorSSale−4.50K$24.87−$111.9K−25.0%13.5K after10b5-1
Jan 17, 2023 (view filing)Jan 125 daysBrege LauraDirectorSSale−12.5K$18.25−$228.1K−100.0%0 after

PCRX Pacira BioSciences, Inc.

Director3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 19, 2024 (view filing)Aug 163 daysBrege LauraDirectorPPurchase+1.00K$12.81+$12.8K+6.0%17.6K after
Jun 7, 2023 (view filing)Jun 52 daysBrege LauraDirectorSSale−600$38.74−$23.2K−5.9%9.55K after10b5-1
Apr 5, 2023 (view filing)Apr 32 daysBrege LauraDirectorSSale−7.00K$40.72−$285.0K−40.8%10.1K after10b5-1